Description: CanSino Biologics Inc. focuses on developing, manufacturing, and commercializing vaccines in the People's Republic of China. Its vaccines include Ad5-EBOV, an Ebola virus vaccine; MCV4 vaccine that is Phase III clinical trial for the prevention of N. meningitides; MCV2 vaccine for treating N. meningitides; DTcP vaccine is for infants, which is in Phase I clinical trails; and DTcP Booster vaccine that is in Phase I clinical trial for addresses the weaker protection preventing pertussis after primary vaccination. The company's product candidates also comprise Tdcp Adolescent and Adult vaccine, which is in Phase I clinical trial for treating pertussis; TB Booster, a 5 adenovirus-based tuberculosis vaccine; PBPV, a serotype-independent protein-based pneumococcal vaccine, which is in Phase I clinical trial; and PCV13i, a pneumococcal conjugate vaccine that is in Phase I clinical trial. It is also developing various preclinical stage products, including CSB016 for treating shingles; CSB014, a combination vaccine; CSB105 to treat meningitis; CSB107 for polio; CSB012 for treating adenovirus; and CSB013 for ZIKA virus. The company has a strategic partnership with Ocugen, Inc. for the development of gene therapy product candidates; and research and development collaboration agreement with BIRD-C Gmbh to explore bacterial ghosts (BGs) as standalone adjuvant to its vaccines, as well as bacterial antigen expressing directly in E. coli carrier BGs to produce new vaccines. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.
Home Page: www.cansinotech.com
401-420, Biomedical Park
Tianjin,
300457
China
Phone:
86 022 5821 3600
Officers
| Name | Title |
|---|---|
| Dr. Xuefeng Yu Ph.D. | Co-Founder, Executive Chairman, CEO & GM |
| Dr. Tao Zhu Ph.D. | Co-Founder, Deputy GM & Chief Scientific Officer |
| Dr. Dongxu Qiu MBA, Ph.D. | Co-Founder, Executive VP & Deputy GM |
| Dr. Shou-Bai Chao Ph.D. | COO, Deputy GM & Executive Director |
| Ms. Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director |
| Mr. Chunlin Xin | Senior Director of New Technology Department |
| Mr. Yonghui Wu | Vice President of Marketing |
| Mr. Jin Cui | Board Secretary |
| Mr. Ming King Chiu FCIS, FCS | Joint Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5466 |
| Price-to-Sales TTM: | 2.1878 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1494 |